Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 23:9:784.
doi: 10.3389/fpsyt.2018.00784. eCollection 2018.

Feasibility, Adherence and Efficacy of Liraglutide Treatment in a Sample of Individuals With Mood Disorders and Obesity

Alessandro Cuomo  1 , Simone Bolognesi  1 , Arianna Goracci  1 , Cristina Ciuoli  1 , Bruno Beccarini Crescenzi  1 , Giuseppe Maina  2 , Gianluca Rosso  2 , Edvige Facchi  3 , Carla Maccora  1 , Nicola Giordano  1 , Valeria Verdino  1 , Andrea Fagiolini  1
Affiliations

Feasibility, Adherence and Efficacy of Liraglutide Treatment in a Sample of Individuals With Mood Disorders and Obesity

Alessandro Cuomo et al. Front Psychiatry. .

Abstract

Background: Liraglutide is a once-daily injectable medication approved for the treatment of obesity. Hereby we report the feasibility, adherence and efficacy of liraglutide treatment in a sample of individuals with mood disorders and obesity. Methods and Sample: Twenty-nine patients with Bipolar or Major Depressive Disorder received liraglutide once daily subcutaneously at a dose gradually titrated from 0.6 to 3 mg. All patients were obese and had previously failed multiple healthy lifestyle interventions, including exercise and diet programs. Patients' weight was recorded before liraglutide treatment (T0) and then 1 (T1), 3 (T3), and 6 months (T6) following T0. Results: Mean baseline (T0) weight was 110.54 Kg (±24.95). Compared to baseline, the percentage of weight loss was 3.37% at T1, 7.85% at T3, and 10.20% at T6. Thirty-one percent (n = 9) of patients had no side effects, 34.48% (n = 10) had one, 24.14% (n = 7) had two, and 10.34% (n = 3) had three side effects. All 29 subjects were still on liraglutide at T1; 79.31 and 48.28% were on liraglutide at T3 and T6. No significant relationship was found between liraglutide dose and likelihood to continue the medication. No patient showed a worsening of the psychiatric condition due to liraglutide treatment. Acceptability and satisfaction with treatment were good for the 48% that completed the study. Conclusions: Liraglutide treatment was efficacious, accepted and tolerated by ~50% of our sample, followed up for a period of 180 days. Larger, longer, controlled, prospective studies are warranted.

Keywords: bipolar; depression; depressive disorder; liraglutide; mood; obesity.

PubMed Disclaimer

References

    1. Newcomer JW. Metabolic syndrome and mental illness. Am J Manag Care (2007) 13:S170–7. - PubMed
    1. Mayor S. Patients with severe mental illness have greatly increased cardiovascular risk, study finds. BMJ (2017) 357:j2339 10.1136/bmj.j2339 - DOI
    1. Weiner M, Warren L, Fiedorowicz JG. Cardiovascular morbidity and mortality in bipolar disorder. Ann Clin Psychiatry (2011) 23:40–7. - PMC - PubMed
    1. De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry (2011) 10:52–77. 10.1002/j.2051-5545.2011.tb00014.x - DOI - PMC - PubMed
    1. Ringen PA, Engh JA, Birkenaes AB, Dieset I, Andreassen OA. Increased mortality in schizophrenia due to cardiovascular disease–a non-systematic review of epidemiology, possible causes, and interventions. Front Psychiatry (2014) 5:137. 10.3389/fpsyt.2014.00137 - DOI - PMC - PubMed